Swiss National Bank
MRSN

Swiss National Bank’s Mersana Therapeutics MRSN Stock Holding History

Swiss National Bank’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,124
Closed -$226K – 2583
2023
Q3 		$226K Hold
7,124
– – ﹤0.01% 2600
2023
Q2 		$586K Buy
7,124
+232
+3% +$33.9K ﹤0.01% 2511
2023
Q1 		$708K Sell
6,892
-616
-8% -$86.5K ﹤0.01% 2421
2022
Q4 		$1.1M Buy
7,508
+148
+2% +$25K ﹤0.01% 2293
2022
Q3 		$1.24M Buy
7,360
+240
+3% +$39K ﹤0.01% 2206
2022
Q2 		$822K Buy
7,120
+1,680
+31% +$158K ﹤0.01% 2464
2022
Q1 		$543K Buy
5,440
+384
+8% +$44.9K ﹤0.01% 2584
2021
Q4 		$786K Buy
5,056
+136
+3% +$26.5K ﹤0.01% 2554
2021
Q3 		$1.16M Buy
4,920
+88
+2% +$25.7K ﹤0.01% 2363
2021
Q2 		$1.64M Sell
4,832
-180
-4% -$68.1K ﹤0.01% 2234
2021
Q1 		$2.03M Buy
5,012
+64
+1% +$31K ﹤0.01% 1990
2020
Q4 		$3.29M Buy
4,948
+316
+7% +$176K ﹤0.01% 1620
2020
Q3 		$2.16M Buy
4,632
+148
+3% +$74.8K ﹤0.01% 1680
2020
Q2 		$2.62M Buy
+4,484
New +$1.53M ﹤0.01% 1554

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Swiss National Bank's MRSN Position: Q4 2023 in Review

Swiss National Bank sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 7,124 shares — an estimated $226K sold.

Swiss National Bank first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $3.29M in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Swiss National Bank reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Swiss National Bank sold 7,124 Mersana Therapeutics shares in Q4 2023, an estimated $226K.
  • Swiss National Bank first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • Swiss National Bank's Mersana Therapeutics position peaked at $3.29M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.